A hemp retailer can pass every audit, hold a current lab report on every product, and still get a termination notice from its processor on a Tuesday morning. The product is federally legal. The sales are real. The bank closes the account anyway. That distance, between a lawful business and a banking system that still refuses to serve it, is the daily reality of selling CBD online, and it traces to causes that have little to do with the merchant.
The Cannabis Shadow
The core problem is association. Hemp-derived CBD comes from the same plant as marijuana, and that resemblance shapes how banks see it. Marijuana remains federally controlled, so card networks and acquiring banks fold CBD into the same risk bucket to stay safe. A compliance officer rarely has the time to parse the difference between a 0.3% THC hemp extract and a controlled substance, so the cautious move is to decline the whole category. Legality on paper does not undo a reputation built by proximity to a banned drug, and that reputation follows even the most careful sellers. The result is that compliance, which should lower risk, barely moves the bank’s decision once the category label is attached.
A Dedicated Provider’s Role
Because mainstream processors treat the category as a liability, the workable answer for most sellers is a provider that specializes in it. A generalist may onboard a store and then drop it once an automated review notices the products, while a specialist has underwritten the risk deliberately and built it into pricing.
A dedicated cbd payment partner reads the category correctly from the start, sets realistic limits, and keeps the account standing through the volume swings that make a generic processor nervous. That stability is worth more than a slightly lower rate that vanishes the moment the account is frozen.
The Regulatory Gap at the Top
Federal policy contradicts itself, and banks pay attention to the contradiction. The 2018 Farm Bill legalized hemp, yet the FDA still bars CBD from foods and dietary supplements and has approved only one cannabidiol product, the seizure drug Epidiolex. Everything else sits in a regulatory gray zone. For a bank, that gray zone is liability, since an agency could change its stance or bring an action at any time. The agency has kept up a steady run of warning letters to sellers making health claims, which banks read as a live enforcement risk attached to the whole category. Until federal guidance is settled, processors price the uncertainty into every CBD account or avoid the category outright.
The Legacy of Bank De-Risking
Some of the caution is historical. Starting in 2013, a federal effort known as Operation Choke Point pressured banks to cut ties with industries seen as high risk, from firearms dealers to payday lenders. The program formally ended in 2017, but the habit it taught did not. Banks learned that serving a flagged category invites regulatory attention, so many now de-risk, refusing whole sectors and declining to weigh merchants one by one. CBD inherited that reflex even after its legal status improved, which is why a clean compliance record often counts for less than the label on the products.
Legislation Stuck in Neutral
Relief keeps stalling in Congress. The SAFER Banking Act, which would shield banks that serve state-legal cannabis and the businesses around it, has advanced through committee and cleared the House more than once, yet it has still never passed the full Senate. Without that protection, banks have no federal cover for the risk they take on, so the safe answer stays no.
The picture shifts slowly elsewhere. A federal move toward a rescheduling order for cannabis could ease some of the pressure, but the banking bill itself remains parked under leadership that opposes it. For now, CBD sellers operate without the legislative backstop that would make mainstream processors comfortable, which keeps them dependent on specialists who choose to take the category on.
The Chargeback Multiplier
The category’s own numbers reinforce the caution. CBD sees higher dispute rates than most retail, partly because some buyers do not recognize the charge on a statement and partly because the products draw impulse purchases that get regretted later. Every chargeback above the card networks’ threshold pushes an account closer to termination and confirms the high-risk label the merchant is trying to shed. The result is a loop. Banks expect trouble, price for it or decline, and the friction that follows produces the very instability they feared, which then becomes the evidence for the next processor’s refusal.
Rolling Reserves and Frozen Funds
Even an approved CBD account rarely runs on normal terms. To cover the risk, a processor often holds a rolling reserve, keeping back a share of each batch, sometimes 5% to 10%, for months before releasing it. That ties up working capital a growing store needs to buy inventory. Worse, a nervous processor can freeze the account during a review and hold the balance, leaving a seller unable to pay suppliers while the money sits untouched. The threat of a freeze, more than the headline rate, is what makes mainstream processing so unreliable for the category, and it pushes sellers toward partners that price for stability instead of surprising them with one.
A System Slower Than the Law
The struggle says less about CBD the product than about a financial system that moves slower than the law. Hemp became legal in 2018, but the rules banks answer to have not caught up, between the FDA’s silence, the unfinished legislation, and the habits left by past crackdowns. Most CBD sellers are lawful operators caught in someone else’s caution. Until the federal picture settles, the way through runs through the processors that already understand the category and price its risk on purpose, which is why the choice of provider often decides if a legal product can actually collect the money it earns. The law changed in 2018, but for most sellers the banking system still has not, and the gap is unlikely to close until Congress or the regulators act.
